Advanced Proteome Therapeutics Corporation

Advanced Proteome Therapeutics Corporation

August 07, 2009 15:40 ET

Advanced Proteome Therapeutics Corporation Enters Into Investor Relations Agreement

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 7, 2009) - Advanced Proteome Therapeutics Corporation (the "Corporation" or "APC") (TSX VENTURE:APC) is pleased to announce that it has retained Gale Capital Corporation ("Gale"), a Vancouver-based company specializing in corporate finance and communications, to provide the Corporation with investor relations services.

The Agreement between the Corporation and Gale (the "IR Agreement") is for a period of three months. Gale is a full and comprehensive provider of corporate finance and investor relations services, and will assist the Corporation in fostering productive, continuing dialogues with analysts, brokers, investors and other financial professionals.

Gale will receive a monthly retainer of $8,000 during the term of the IR Agreement, for an aggregate consideration of $24,000. The Corporation has also granted an option to purchase up to 600,000 common shares to Gale, exercisable for a period of two years at an exercise price of $0.30 per share. The options are granted pursuant to the Corporation's Stock Option Plan and will vest in accordance with the provisions therein and the policies of the TSX Venture Exchange.

The IR Agreement is subject to review and approval by the TSX Venture Exchange.


Gale is a leading provider of outsourced investor relations to Canadian public companies. Gale's strength is its disciplined marketing approach to the development and execution of strategic, customized investor relations programs.

About Advanced Proteome Therapeutics Corp. (APC).

APC's primary corporate mission is to apply its proprietary drug delivery and drug redevelopment technologies to produce new, improved versions of therapeutic proteins and pioneer the emerging field of protein-site targeting for commercially relevant applications. The market for therapeutic proteins and peptides is expected to surpass more than 50 Billion USD by the year 2010 and is the fastest growing segment of the pharmaceutical market. Future growth however depends largely on the industry overcoming a number of hurdles, including drug delivery challenges.


Alexander (Allen) Krantz, President and Chief Executive Officer

The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information